Farmacias Benavides, S.A. (BEVIDESB) Fair Value & Analysis
Healthcare · MX · Market cap 10.2B MXN
Fair value as of: Jul 12, 2026
From 26 valuation models · updated 28 days ago
Share price −3.8% over the past month.
A solid business, but screening 34% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (20.65 MXN). The favourable scenario is already priced in.
- Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.
How to read this chart
60‑month range 8.30 MXN – 26.00 MXN · fair‑value band 12.39 MXN – 20.65 MXN · the 25.00 MXN price screens above the 16.52 MXN fair value. Dashed = 300-day average. As of Jul 12, 2026.
Analysis
Farmacias Benavides, S.A. (BEVIDESB) currently trades at 25.00 MXN, while our model-based Fair Value estimate is 16.52 MXN, implying the stock looks roughly 33.9% overvalued today. The Quality Score stands at 61/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Farmacias Benavides, S.A. generated revenue of 20.7B MXN at a net margin of 2.2%. Revenue grew 28.5% year over year. It earns a return on equity of 59.8%. Net debt stands at 289M MXN. Fundamentals as of Jul 12, 2026
Our scenario range runs from 12.39 MXN (bear case) to 20.65 MXN (bull case); at 25.00 MXN, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 4% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at -34%, BEVIDESB screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (29.42 MXN) versus Asset-Based (0.7800 MXN). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 58 · Market factors (momentum, volatility) 51
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Farmacias Benavides, S.A.B. de C.V. engages in the retail of health and wellness products. The company also provides medicamentos, non-perishable food, and hygiene and beauty products, as well as photography. The company was founded in 1917 and is based in Monterrey, Mexico. Farmacias Benavides, S.A.B. de C.V.
Full company description
Farmacias Benavides, S.A.B. de C.V. engages in the retail of health and wellness products. The company also provides medicamentos, non-perishable food, and hygiene and beauty products, as well as photography. The company was founded in 1917 and is based in Monterrey, Mexico. Farmacias Benavides, S.A.B. de C.V. operates as a subsidiary of Walgreens Boots Alliance, Inc.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2019 – FY2023 · reported fiscal years
Farmacias Benavides, S.A. reported revenue of 17.2B MXN in FY2023 versus 13.9B MXN in FY2019, a compound +5.5%/yr. Reported net income was 282M MXN in FY2023.
BEVIDESB screens 34% overvalued. Compare with JD Health International Inc →
Peer Group
Pharmaceutical Retailers · 61 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc 6618 | HK$39.20 | HK$33.28 | -15% |
| Raia Drogasil S.A RADL3 | R$18.20 | R$15.58 | -14% |
| Yifeng Pharmacy Chain Co 603939 | ¥20.24 | ¥29.07 | +44% |
| DaShenLin Pharmaceutical Group 603233 | ¥17.81 | ¥23.86 | +34% |
| Corporativo Fragua, S.A. FRAGUAB | 463.00 MXN | 821.18 MXN | +77% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥11.51 | ¥10.57 | -8% |
| MedPlus Health Services Limited MEDPLUS | ₹690.20 | ₹379.25 | -45% |
| Yixintang Pharmaceutical Group 002727 | ¥11.46 | ¥9.45 | -18% |
| Anhui Huaren Health Pharmaceutical Co 301408 | ¥14.40 | ¥10.05 | -30% |
| Apotea AB APOTEA | kr 74.75 | kr 43.95 | -41% |
Compare Farmacias Benavides, S.A. with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Farmacias Benavides, S.A. (BEVIDESB) overvalued or undervalued?
What is the fair value of BEVIDESB?
What is the quality score of BEVIDESB?
What is the revenue of Farmacias Benavides, S.A. (BEVIDESB)?
What is the net profit margin of BEVIDESB?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Farmacias Benavides, S.A. and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.